Register Now: Engineering LNP's Beyond the Liver for Genetic Medicines
|Articles|December 5, 2019

Horizon Discovery Partners with HPA to Expand Open Access Resource

Horizon Discovery has announced its partnership with the Human Protein Atlas, which will see the incorporation of Horizon’s CRISPR-edited knockout cell models into the Cell Atlas program.

In a Dec. 3, 2019 press release, Horizon Discovery has announced its partnership with the Human Protein Atlas, which will see the incorporation of Horizon’s CRISPR-edited knockout cell models into the Cell Atlas program.

Through the integration of the knockout cell models into the Cell Atlas program, it is hoped that understanding of genetic drivers of disease will be advanced. Additionally, knockout cell models offer a possibility of enhanced validation of antibodies based on genetic strategies as a result of the absence of the targeting protein, which correlates with a loss of signal for specific antibodies.

“Horizon has over a decade of experience in gene editing, and a well-established reputation for providing CRISPR-edited knockout cell models,” said Professor Emma Lundberg, who is responsible for the HPA Cell Atlas program, in the press release. “We have previously used Horizon’s cell lines in our high throughput imaging processes with great success. Using a validated gene-edited cell line where all cell models have the same background will be key to maximizing efficiency and achieving data reproducibility.” 

Terry Pizzie, CEO, Horizon Discovery, added, “Having contributed to several thousands of publications in the field of human biology and disease, the HPA is a highly regarded knowledge provider and an expert in the field of molecular mechanisms of the human cell. We are delighted to partner with HPA to provide the robust research tools required to extend their database, and we are proud to be contributing to the expansion of this renowned open access resource for both academia and industry.”

Source: Horizon

 


Related to this article

The BioPharm Brief: Survival, Gene Editing, and Skin Cancer
This episode of the BioPharm Brief highlights Roche’s Tam-Peli phase 3 survival data in relapsed small-cell lung cancer, Cellectis’ shift to in vivo gene editing for lipid disorders, and Phio Pharmaceuticals’ FDA briefing package for PH-762 in cutaneous squamous cell carcinoma.
Stainless steel bioreactor vessels in a manufacturing facility. | Image Credit: © Corona Borealis - stock.adobe.com
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.